University of Hertfordshire

From the same journal

By the same authors

Clinical and neurocognitive changes with modafinil in obsessive–compulsive disorder : a case report

Research output: Contribution to journalArticlepeer-review

Standard

Clinical and neurocognitive changes with modafinil in obsessive–compulsive disorder : a case report. / Dittrich, W.; Johansen, T.; Padhi, A.; Smith, I.E.; Chamberlain, S.R.; Fineberg, Naomi.

In: Psychopharmacology, Vol. 212, No. 3, 2010, p. 449-451.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Dittrich, W. ; Johansen, T. ; Padhi, A. ; Smith, I.E. ; Chamberlain, S.R. ; Fineberg, Naomi. / Clinical and neurocognitive changes with modafinil in obsessive–compulsive disorder : a case report. In: Psychopharmacology. 2010 ; Vol. 212, No. 3. pp. 449-451.

Bibtex

@article{57bd8264b69b46bd9b809aae8ff9441c,
title = "Clinical and neurocognitive changes with modafinil in obsessive–compulsive disorder : a case report",
abstract = "There are limited treatment options for co-occurring sleep disorders and obsessive-compulsive disorder (OCD). We postulated that Modafinil (Provigil) [2-{(diphenylmethyl) sulfinyl acetamide}] a non-amphetamine wakefulness-promoting agent, might be of value in patients with excessive daytime sleepiness (EDS). Randomized double-blind placebo controlled depression trials have investigated the effects of modafinil co-administered with selective serotonin re-uptake inhibitors (SSRIs) and found improvement in clinical global scores and, aside from effects on sleep and mood, modafinil has exhibited cognitive enhancing effects in some subjects (Minzenberg and Carter, 2008). In a double-blind placebo-controlled crossover challenge, Turner et al. (2004) demonstrated decreased motor impulsivity as measured on laboratory tests in adult attention-deficit/hyperactivity disorder patients treated with single doses of modafinil (100 mg and 200 mg). To date, studies examining the neuropsychological effects of treatment are rare in OCD and have generally failed to show a positive effect of SSRI treatment on cognition (Nielen and den Boer 2003). In this context, we considered a new approach for treating neurocognitive impairments in treatment-resistant OCD. Modafinil{\textquoteright}s effects on clinical symptoms and on a selected range of neurocognitive functions previously reported to be impaired in OCD (Chamberlain et al. 2005) are examined. We report the case of a patient with treatment-resistant OCD and EDS treated with adjunctive modafinil.",
author = "W. Dittrich and T. Johansen and A. Padhi and I.E. Smith and S.R. Chamberlain and Naomi Fineberg",
note = "The original publication is available at www.springerlink.com Copyright Springer",
year = "2010",
doi = "10.1007/s00213-010-1958-9",
language = "English",
volume = "212",
pages = "449--451",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

RIS

TY - JOUR

T1 - Clinical and neurocognitive changes with modafinil in obsessive–compulsive disorder : a case report

AU - Dittrich, W.

AU - Johansen, T.

AU - Padhi, A.

AU - Smith, I.E.

AU - Chamberlain, S.R.

AU - Fineberg, Naomi

N1 - The original publication is available at www.springerlink.com Copyright Springer

PY - 2010

Y1 - 2010

N2 - There are limited treatment options for co-occurring sleep disorders and obsessive-compulsive disorder (OCD). We postulated that Modafinil (Provigil) [2-{(diphenylmethyl) sulfinyl acetamide}] a non-amphetamine wakefulness-promoting agent, might be of value in patients with excessive daytime sleepiness (EDS). Randomized double-blind placebo controlled depression trials have investigated the effects of modafinil co-administered with selective serotonin re-uptake inhibitors (SSRIs) and found improvement in clinical global scores and, aside from effects on sleep and mood, modafinil has exhibited cognitive enhancing effects in some subjects (Minzenberg and Carter, 2008). In a double-blind placebo-controlled crossover challenge, Turner et al. (2004) demonstrated decreased motor impulsivity as measured on laboratory tests in adult attention-deficit/hyperactivity disorder patients treated with single doses of modafinil (100 mg and 200 mg). To date, studies examining the neuropsychological effects of treatment are rare in OCD and have generally failed to show a positive effect of SSRI treatment on cognition (Nielen and den Boer 2003). In this context, we considered a new approach for treating neurocognitive impairments in treatment-resistant OCD. Modafinil’s effects on clinical symptoms and on a selected range of neurocognitive functions previously reported to be impaired in OCD (Chamberlain et al. 2005) are examined. We report the case of a patient with treatment-resistant OCD and EDS treated with adjunctive modafinil.

AB - There are limited treatment options for co-occurring sleep disorders and obsessive-compulsive disorder (OCD). We postulated that Modafinil (Provigil) [2-{(diphenylmethyl) sulfinyl acetamide}] a non-amphetamine wakefulness-promoting agent, might be of value in patients with excessive daytime sleepiness (EDS). Randomized double-blind placebo controlled depression trials have investigated the effects of modafinil co-administered with selective serotonin re-uptake inhibitors (SSRIs) and found improvement in clinical global scores and, aside from effects on sleep and mood, modafinil has exhibited cognitive enhancing effects in some subjects (Minzenberg and Carter, 2008). In a double-blind placebo-controlled crossover challenge, Turner et al. (2004) demonstrated decreased motor impulsivity as measured on laboratory tests in adult attention-deficit/hyperactivity disorder patients treated with single doses of modafinil (100 mg and 200 mg). To date, studies examining the neuropsychological effects of treatment are rare in OCD and have generally failed to show a positive effect of SSRI treatment on cognition (Nielen and den Boer 2003). In this context, we considered a new approach for treating neurocognitive impairments in treatment-resistant OCD. Modafinil’s effects on clinical symptoms and on a selected range of neurocognitive functions previously reported to be impaired in OCD (Chamberlain et al. 2005) are examined. We report the case of a patient with treatment-resistant OCD and EDS treated with adjunctive modafinil.

U2 - 10.1007/s00213-010-1958-9

DO - 10.1007/s00213-010-1958-9

M3 - Article

VL - 212

SP - 449

EP - 451

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -